文献速递乳腺癌

在接受帕博西尼和内分泌治疗的HR+ HER2-转移性乳腺癌患者中,CANKADO PRO-React电子健康支持显著延长生活质量至恶化时间:多中心随机AGO-B WSG PreCycle试验的主要结局分析

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
PubMed 文献 · Ann Oncol · 2023-05-16

这项多中心随机IV期试验纳入499例接受帕博西尼联合内分泌治疗的HR+ HER2-局部晚期或转移性乳腺癌患者,按2:1随机分配至CANKADO-active组或CANKADO-inform组,主要终点为生活质量至恶化时间。CANKADO-active组生活质量恶化累积发生率显著更低(HR 0.698,95%CI 0.506-0.963),无进展生存期和总生存期两组无显著差异。

要点

  • CANKADO-active组生活质量恶化风险显著低于CANKADO-inform组(HR 0.698,95%CI 0.506-0.963)。
  • 一线亚组HR 0.716(95%CI 0.484-1.060,P=0.09),二线亚组HR 0.661(95%CI 0.374-1.168,P=0.2)。
  • 两组临床结局无显著差异:中位PFS 21.4 vs 18.7个月,中位OS未达到 vs 42.6个月。

核心结论

  • PreCycle是首个多中心随机电子健康试验,证明在接受口服肿瘤治疗的转移性乳腺癌患者中使用交互式自主患者赋能应用程序可显著改善生活质量至恶化时间。

研究设计与样本

  • 多中心、随机、IV期、组间AGO-B WSG PreCycle试验(NCT03220178),2017年至2021年间从71个中心纳入499例患者(中位年龄59岁),按2:1随机分配至CANKADO-active组或CANKADO-inform组,按治疗线数分层。
  • 412例患者(CANKADO-active组271例,CANKADO-inform组141例)可用于主要终点分析,主要终点为生活质量至恶化时间(FACT-G评分下降10分),采用Aalen-Johansen估计量计算累积发生率函数及95%逐点置信区间。

主要发现

  • 在全部患者(ITT-ePRO)中,CANKADO-active组生活质量恶化累积发生率显著更低(HR 0.698,95%CI 0.506-0.963)。
  • 一线患者(n=295)中HR为0.716(95%CI 0.484-1.060,P=0.09),二线患者(n=117)中HR为0.661(95%CI 0.374-1.168,P=0.2)。
  • FACT-G完成率在约第30次访视前保持在80%及以上,平均FACT-G评分自基线持续下降,CANKADO-active组表现出有利的偏移。
  • 两组临床结局无显著差异:ITT人群中位PFS在CANKADO-active组为21.4个月(95%CI 19.4-23.7),CANKADO-inform组为18.7个月(95%CI 15.1-23.5);中位OS在CANKADO-active组未达到,CANKADO-inform组为42.6个月。

局限性

  • FACT-G完成率在后期访视中绝对患者数下降,约第30次访视后完成率降至80%以下。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality of life (QoL) in hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer (MBC) patients receiving palbociclib and an aromatase inhibitor or palbociclib + fulvestrant. CANKADO PRO-React, a European Union-registered medical device, is an interactive autonomous application reacting to patient self-reported observations. PATIENTS AND METHODS: Between 2017 and 2021, 499 patients (median age 59 years) from 71 centers were randomized (2 : 1, stratified by therapy line) between an active version of CANKADO PRO-React (CANKADO-active arm) and a version with limited functionality (CANKADO-inform arm). A total of 412 patients (271 CANKADO-active; 141 CANKADO-inform) were available for analysis of the primary endpoint, time to deterioration (TTD) of QoL [10-point drop on the Functional Assessment of Cancer Therapy-General (FACT-G) score], using an Aalen-Johansen estimator for cumulative incidence function of TTD DQoL (QoL deterioration) with 95% pointwise confidence intervals (CIs). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and DQoL. RESULTS: In all patients [intention-to-treat (ITT)-ePRO], cumulative incidence of DQoL was significantly more favorable (lower) in the CANKADO-active arm (hazard ratio 0.698, 95% CI 0.506-0.963). Among first-line patients (n = 295), the corresponding hazard ratio was 0.716 (0.484-1.060; P = 0.09), and in second-line patients (n = 117) it was 0.661 (0.374-1.168; P = 0.2). Absolute patient numbers declined in later visits; FACT-G completion rates were 80% and higher until about visit 30. Mean FACT-G scores showed a steady decline from baseline and an offset in favor of CANKADO-active. No significant differences in clinical outcome were observed between arms: median PFS (ITT population) was 21.4 (95% CI 19.4-23.7) (CANKADO-active) and 18.7 (15.1-23.5) months (CANKADO-inform); median OS was not reached (CANKADO-active) and 42.6 months (CANKADO-inform). CONCLUSIONS: PreCycle is the first multicenter randomized eHealth trial demonstrating a significant benefit for MBC patients receiving oral tumor therapy when using an interactive autonomous patient empowerment application.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Harbeck N, Fasching PA, Wuerstlein R, et al. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial. Ann Oncol. 2023. PMID: 37201751. doi:10.1016/j.annonc.2023.05.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。